Efficacy and safety of glucagon-like peptide-1 receptor agonists for treating polycystic ovary syndrome: a Meta-analysis

Abstract

Objective To systematically review the efficacy and safety of glucagon-like peptide-1 (GLP-1)receptor agonists for treating polycystic ovary syndrome (PCOS). Methods PubMed, EMbase, The Cochrane Library, Wanfang Data and CNKI were searched online to collect randomized controlled trials (RCTs) of GLP-1 receptor agonists for treating PCOS from the data of their establishment to Apirl 2018. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then results of Meta-analysis were performed by using RevMan5.3 software. Results A total of 8 RCTs was included. The meta-analysis showed that compared with metformin, GLP-1 receptor agonists were more effective in reducing body mass index (BMI) (MD=-1.61, 95%CI=-2.28—-0.94,P 0.05). Conclusion GLP-1 receptor agonists are superior to metformin in reducing BMI and abdominal girth, improving insulin sensitivity and lowering serum total testosterone in PCOS patients. However, the incidence of adverse events such as nausea and headache is higher. Key words: Polycystic ovary syndrome; Metformin; Meta-analysis; Randomized controlled trial; GLP-1 receptor agonists; Systematic review